Shushu Wang
Chongqing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Efficacy, safety, and biomarkers of neoadjuvant trastuzumab and pertuzumab combined with chemotherapy in Chinese patients with HER2-positive breast cancer: a multicenter retrospective cohort study.
Journal: International journal of surgery (London, England)
Published: May 28, 2025
Safety and efficacy of anlotinib combined with taxane and lobaplatin in neoadjuvant treatment of clinical stage II/III triple-negative breast cancer in China (the neoALTAL trial): a single-arm, phase 2 trial.
Journal: EClinicalMedicine
Published: December 15, 2023
Construction of a ferroptosis-based prognostic model for breast cancer helps to discriminate high/low risk groups and treatment priority.
Journal: Frontiers in immunology
Published: July 20, 2023
Lobaplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: a 5-year follow-up of a randomized, open-label, phase II trial.
Journal: Therapeutic advances in medical oncology
Published: September 23, 2021
Overexpression of Tumor Protein p53-regulated Apoptosis-inducing Protein 1 Regulates Proliferation and Apoptosis of Breast Cancer Cells through the PI3K/Akt Pathway.
Journal: Journal of breast cancer
Published: July 04, 2018
Triple Negative Breast Cancer Depends on Sphingosine Kinase 1 (SphK1)/Sphingosine-1-Phosphate (S1P)/Sphingosine 1-Phosphate Receptor 3 (S1PR3)/Notch Signaling for Metastasis.
Journal: Medical science monitor : international medical journal of experimental and clinical research
Published: April 02, 2018
Downregulation of Dock1 and Elmo1 suppresses the migration and invasion of triple-negative breast cancer epithelial cells through the RhoA/Rac1 pathway.
Journal: Oncology letters
Published: December 05, 2017
SPHK1 promotes metastasis of thyroid carcinoma through activation of the S1P/S1PR3/Notch signaling pathway.
Journal: Experimental and therapeutic medicine
Published: August 06, 2017
A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer.
Journal: Nature communications
Published: March 22, 2017
Sphk1 promotes breast epithelial cell proliferation via NF-κB-p65-mediated cyclin D1 expression.
Journal: Oncotarget
Published: August 08, 2016
Neoadjuvant Chemotherapy Creates Surgery Opportunities For Inoperable Locally Advanced Breast Cancer.
Journal: Scientific reports
Published: July 11, 2016
Last Updated: 09/26/2026